William Blair & Company
IKT icon

William Blair & Company’s Inhibikase Therapeutics IKT Stock Holding History

William Blair & Company’s Portfolio IKT Stock Details IKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$265K Buy
157,988
+5,035
+3% +$8.94K ﹤0.01% 1379
2025
Q4 		$314K Hold
152,953
– – ﹤0.01% 1289
2025
Q3 		$248K Sell
152,953
-4,000
-3% -$6.93K ﹤0.01% 1383
2025
Q2 		$306K Buy
156,953
+1,000
+0.6% +$1.96K ﹤0.01% 1252
2025
Q1 		$342K Buy
155,953
+21,000
+16% +$52.8K ﹤0.01% 1206
2024
Q4 		$439K Buy
134,953
+8,833
+7% +$22K ﹤0.01% 1135
2024
Q3 		$164K Buy
126,120
+10,000
+9% +$13.4K ﹤0.01% 1474
2024
Q2 		$141K Buy
116,120
+39,519
+52% +$68.1K ﹤0.01% 1463
2024
Q1 		$165K Buy
76,601
+16,333
+27% +$36K ﹤0.01% 1439
2023
Q4 		$76.5K Buy
60,268
+893
+2% +$924 ﹤0.01% 1537
2023
Q3 		$82.5K Buy
59,375
+1,487
+3% +$3.33K ﹤0.01% 1528
2023
Q2 		$209K Buy
57,888
+11,888
+26% +$44.3K ﹤0.01% 1391
2023
Q1 		$181K Buy
46,000
+7,833
+21% +$32.7K ﹤0.01% 1418
2022
Q4 		$115K Buy
38,167
+8,334
+28% +$33.1K ﹤0.01% 1467
2022
Q3 		$163K Buy
29,833
+25,666
+616% +$135K ﹤0.01% 1430
2022
Q2 		$19K Buy
+4,167
New +$24.6K ﹤0.01% 1733

Other funds holding IKT

SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $437M AUM
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

William Blair & Company's IKT Position: Q1 2026 in Review

William Blair & Company increased its Inhibikase Therapeutics (IKT) stake by 3.3% in Q1 2026, buying an estimated $8.94K and bringing the position to 157,988 shares worth $265K. The position accounts for ﹤0.01% of the portfolio, ranked #1379.

William Blair & Company first reported a position in IKT in Q2 2022 and has held it in 16 quarters since. The position peaked at $439K in Q4 2024. 104 funds tracked by Wall St. Rank hold IKT as of Q1 2026.

  • William Blair & Company held 157,988 shares of Inhibikase Therapeutics worth $265K as of Q1 2026.
  • William Blair & Company bought 5,035 Inhibikase Therapeutics shares in Q1 2026, an estimated $8.94K.
  • Inhibikase Therapeutics made up ﹤0.01% of William Blair & Company's portfolio in Q1 2026, its #1379 holding.
  • William Blair & Company first reported a position in Inhibikase Therapeutics in Q2 2022 and has held it in 16 quarters since.
  • William Blair & Company's Inhibikase Therapeutics position peaked at $439K in Q4 2024.
  • 104 funds tracked by Wall St. Rank held Inhibikase Therapeutics as of Q1 2026.

Based on William Blair & Company's 13F filing for Q1 2026, filed 8 May 2026.